{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination can create an interferon-rich inflammatory state that sensitizes tumors to immune checkpoint blockade",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy",
          "line_ref": "L11"
        },
        {
          "quote": "Type I interferon response score (normalized units) 3.1 vs 1.0 - Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit",
          "line_ref": "L39"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors, and some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings"
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination triggers broader antigen presentation on MHC-I, improving tumor visibility to T cells",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome 62.3% vs 37.3% - Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome 40.6% vs 20.6% - Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        },
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase",
          "line_ref": "L43"
        }
      ],
      "caveat": "Immunopeptidomics readouts may vary across different tumor types and model systems"
    },
    {
      "claim_id": "C03",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in patients receiving immune checkpoint inhibitor therapy",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value p=0.01 - Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely",
          "line_ref": "L49"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized with varied vaccination timing relative to ICI initiation and tumor-type mix heterogeneity, limiting causal interpretation"
    },
    {
      "claim_id": "C04",
      "claim": "PD-L1 pathway activity increases following mRNA vaccination, creating rationale for combining with checkpoint blockade",
      "strength": "strong",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue 2.4x vs 1.0x - Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade",
          "line_ref": "L45"
        }
      ],
      "caveat": "PD-L1 induction was measured in specific model systems and may not be uniform across all tumor types"
    },
    {
      "claim_id": "C05",
      "claim": "The mRNA component specifically is required for sensitization, as lipid particles alone do not produce the effect",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Lipid particle controls lacking mRNA did not reproduce the sensitization effect",
          "line_ref": "L38"
        },
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling",
          "line_ref": "L42"
        }
      ],
      "caveat": "Specific lipid particle formulations may vary in their immunogenicity independent of mRNA content"
    }
  ]
}
